Related Experiment Videos

Approach to steroid-dependent and steroid-refractory Crohn's disease

G R Lichtenstein¹

¹Department of Medicine, Center of Inflammatory Bowel Diseases, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, 3 Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.

Journal of Pediatric Gastroenterology and Nutrition

|November 1, 2001

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.

Alimentary pharmacology & therapeutics·2014

Increased expression of interleukin-8 mRNA in ulcerative colitis and Crohn's disease mucosa and epithelial cells.

Inflammatory bowel diseases·2013

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.

Alimentary pharmacology & therapeutics·2012

Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.

Alimentary pharmacology & therapeutics·2011

Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.

Alimentary pharmacology & therapeutics·2011

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.

Alimentary pharmacology & therapeutics·2011

See all related articles